keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal

keyword
https://www.readbyqxmd.com/read/27913869/ranibizumab-for-vascularized-pigment-epithelial-detachment-1-year-anatomic-and-functional-results
#1
Olivier Chevreaud, Hassiba Oubraham, Salomon Y Cohen, Camille Jung, Rocio Blanco-Garavito, Farah Gherdaoui, Eric H Souied
PURPOSE: To assess the anatomical and functional efficacy of ranibizumab on vascularized pigment epithelial detachment (V-PED) secondary to neovascular age-related macular degeneration (nAMD). METHODS: One hundred and nine patients (116 eyes) were retrospectively selected from medical records of 2097 patients who benefited from intravitreal injection between January 2011 and June 2013 in a tertiary-care University-based Department of Ophthalmology. Inclusion criteria were: nAMD, treatment-naive eyes, presence of V-PED higher than 250 μm, intravitreal ranibizumab with a loading phase, followed by a pro-re-nata regimen, and 1-year follow-up...
December 3, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27913441/size-and-vitreomacular-attachment-of-primary-full-thickness-macular-holes
#2
Elise Philippakis, Franck Amouyal, Aude Couturier, Elise Boulanger-Scemama, Alain Gaudric, Ramin Tadayoni
PURPOSE: To study the relationship between the size of primary full-thickness macular hole (MH) and the vitreomacular attachment status. DESIGN: Single-centre retrospective observational case series. METHODS: The records of 100 consecutive eyes operated for primary full-thickness MH were retrospectively reviewed. The vitreous status and MH diameter were assessed on the preoperative optical coherence tomography scans. MH were classified depending on the presence or absence of vitreomacular traction (VMT) and their size as small (<250 µm), medium (250-400 µm) and large (>400 µm), as suggested in the International VMT Study Group Classification...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27913439/retinitis-pigmentosa-associated-cystoid-macular-oedema-pathogenesis-and-avenues-of-intervention
#3
REVIEW
S Strong, G Liew, M Michaelides
Hereditary retinal diseases are now the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales, of which retinitis pigmentosa (RP) is the most common disorder. RP may be complicated by cystoid macular oedema (CMO), causing a reduction of central vision. The underlying pathogenesis of RP-associated CMO (RP-CMO) remains uncertain, however, several mechanisms have been proposed, including: (1) breakdown of the blood-retinal barrier, (2) failure (or dysfunction) of the pumping mechanism in the retinal pigment epithelial, (3) Müller cell oedema and dysfunction, (4) antiretinal antibodies and (5) vitreous traction...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27912913/intravitreal-therapies-for-non-neovascular-age-related-macular-degeneration-with-intraretinal-or-subretinal-fluid
#4
M Cuesta-Lasso, A Vieira-Barros, R Dolz-Marco, M J Roig-Revert, J Badal, L Amselem, M Díaz-Llopis, R Gallego-Pinazo
OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography...
November 29, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/27911446/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#5
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used to identify treatment-naive patients receiving ranibizumab intravitreal injections or dexamethasone intravitreal implants between June 2010 and February 2014 who had 12 months of follow-up data...
December 2, 2016: Eye
https://www.readbyqxmd.com/read/27911420/-role-of-immunological-factors-in-the-development-of-myopic-choroidal-neovascularization
#6
A G Shchuko, N V Zaitseva, T N Yur'eva, E R Chernykh, I M Mikhalevich, A V Grigor'eva
AIM: To study the concentration of cytokines in the aqueous humor of the anterior chamber in patients with myopic choroidal neovascularization (mCNV) and to compare the results to their ophthalmic status. MATERIAL AND METHODS: A total of 19 patients (19 eyes) with mCNV treated with intravitreal ranibizumab were included in the study. The control group consisted of 15 patients (15 eyes) with myopia who had cataract surgery. Age, sex, and refractive error distribution were similar to that in the study group...
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27911131/outcomes-of-patients-initially-treated-with-intravitreal-bevacizumab-for-central-retinal-vein-occlusion-long-term-follow-up
#7
Dan Călugăru, Mihai Călugăru
No abstract text is available yet for this article.
December 2, 2016: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/27908408/protective-effect-of-magnesium-acetyltaurate-against-nmda-induced-retinal-damage-involves-restoration-of-minerals-and-trace-elements-homeostasis
#8
Azliana Jusnida Ahmad Jafri, Natasha Najwa Nor Arfuzir, Lidawani Lambuk, Igor Iezhitsa, Renu Agarwal, Puneet Agarwal, Norhafiza Razali, Anna Krasilnikova, Maria Kharitonova, Vasily Demidov, Evgeny Serebryansky, Anatoly Skalny, Alexander Spasov, Ahmad Pauzi Md Yusof, Nafeeza Mohd Ismail
Glutamate-mediated excitotoxicity involving N-methyl-d-aspartate (NMDA) receptors has been recognized as a final common outcome in pathological conditions involving death of retinal ganglion cells (RGCs). Overstimulation of NMDA receptors results in influx of calcium (Ca) and sodium (Na) ions and efflux of potassium (K). NMDA receptors are blocked by magnesium (Mg). Such changes due to NMDA overstimulation are also associated with not only the altered levels of minerals but also that of trace elements and redox status...
January 2017: Journal of Trace Elements in Medicine and Biology
https://www.readbyqxmd.com/read/27906070/subretinal-adipose-tissue-derived-mesenchymal-stem-cell-implantation-in-advanced-stage-retinitis-pigmentosa-a-phase-i-clinical-safety-study
#9
Ayse Oner, Z Burcin Gonen, Neslihan Sinim, Mustafa Cetin, Yusuf Ozkul
BACKGROUND: This prospective clinical case series aimed to investigate the safety of subretinal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in advanced stage retinitis pigmentosa (RP). METHODS: This study included 11 patients with end-stage RP who received subretinal implantation of ADMSCs. All patients had a total visual field defect and five of them only had light perception. The best corrected visual acuity (BCVA) in the study was 20/2000...
December 1, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27905340/effect-of-prophylactic-intraocular-pressure-lowering-medication-brinzolamide-on-intraocular-pressure-after-ranibizumab-intravitreal-injection-a-case-control-study
#10
Shuang Song, Xiao-Bing Yu, Hong Dai
PURPOSE: To observe the effect of prophylactic intraocular pressure (IOP)-lowering medication (brinzolamide) on IOP after ranibizumab intravitreal injections (IVIs). MATERIALS AND METHODS: This prospective case-control study included 352 eyes from 352 patients (1 eye per patient) who were treated with ranibizumab intravitreal injection and divided randomly into two groups. Two hundred and three patients in control group only received the ranibizumab IVI, but 149 patients in case group received one drop of prophylactic intraocular brinzolamide preinjection...
October 2016: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/27904503/stem-cell-ophthalmology-treatment-study-scots-bone-marrow-derived-stem-cells-in-the-treatment-of-leber-s-hereditary-optic-neuropathy
#11
Jeffrey N Weiss, Steven Levy, Susan C Benes
The Stem Cell Ophthalmology Treatment Study (SCOTS) is currently the largest-scale stem cell ophthalmology trial registered at ClinicalTrials.gov (identifier: NCT01920867). SCOTS utilizes autologous bone marrow-derived stem cells (BMSCs) to treat optic nerve and retinal diseases. Treatment approaches include a combination of retrobulbar, subtenon, intravitreal, intra-optic nerve, subretinal, and intravenous injection of autologous BMSCs according to the nature of the disease, the degree of visual loss, and any risk factors related to the treatments...
October 2016: Neural Regeneration Research
https://www.readbyqxmd.com/read/27903073/comparison-between-early-or-late-intravitreal-injection-of-dexamethasone-implant-in-branch-brvo-or-central-crvo-retinal-vein-occlusion-six-months-follow-up
#12
Fernanda Pacella, Giuseppe La Torre, Stefania Basili, Monica Autolitano, Antonella Pascarella, Tommaso Lenzi, Elena Pacella
PURPOSE: The purpose of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-month follow-up. We assessed whether an earlier treatment start (within 7 days from diagnosis) could be more beneficial than a delayed (or late) treatment start (after 7 days). MATERIALS AND METHODS: The study included 81 patients (81 eyes) affected by retinal vein occlusion...
November 30, 2016: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/27902539/cystoid-macular-edema-and-cystoid-macular-degeneration-as-a-result-of-multiple-pathogenic-factors-in-the-setting-of-central-serous-chorioretinopathy
#13
Polina Astroz, Chandrakumar Balaratnasingam, Lawrence A Yannuzzi
PURPOSE: To report the pathogenic factors that account for cystoid macular edema and cystoid macular degeneration in chronic central serous chorioretinopathy (CSC). METHODS: The clinical course and multimodal imaging findings, including fundus color photography, fundus autofluorescence, spectral-domain optical coherence tomography, and fluorescein angiography, of one eye with cystoid macular edema due to chronic CSC was documented. RESULTS: A 44-year old woman with a history of chronic CSC presented with progressive visual decline in the right eye...
November 29, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27901006/intravitreal-ranibizumab-for-aggressive-posterior-retinopathy-of-prematurity
#14
Xiu-Juan Li, Xiao-Peng Yang, Shuang Sun, Xiao-Bei Lyu, Heng Jia
No abstract text is available yet for this article.
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27898619/alternative-chemotherapeutic-agents-for-the-treatment-of-retinoblastoma-using-the-intra-arterial-and-intravitreal-routes-a-path-forward-toward-drug-discovery
#15
Shuai Yuan, Debra L Friedman, Anthony B Daniels
No abstract text is available yet for this article.
2017: International Ophthalmology Clinics
https://www.readbyqxmd.com/read/27898414/outcomes-after-a-1-year-treatment-with-ranibizumab-for-diabetic-macular-edema-in-a-clinical-setting
#16
Linda Hrarat, Franck Fajnkuchen, Marouane Boubaya, Vincent Lévy, Valérie Sarda, Typhaine Grenet, Sylvia Nghiem-Buffet, Gilles Chaine, Audrey Giocanti-Auregan
PURPOSE: The aim of this study was to assess the efficacy and safety of ranibizumab in patients with diabetic macular edema (DME). METHODS: We conducted a retrospective analysis of consecutive patients with vision loss due to DME who were treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as-needed basis. The primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and the number of intravitreal injections (IVI) at 12 months...
November 30, 2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27897120/dropless-cataract-surgery-an-overview
#17
Richard L Lindstrom, M Stewart Galloway, Andrzej Grzybowski, Jeffrey T Liegner
Risk reduction and the attainment of good outcomes in contemporary cataract surgery depend in part on patient compliance with a postoperative regimen of topical eye drops. Topical drops are expensive and challenging to instill properly for patients. The consequences of noncompliance or poor compliance can be significant for the patient (in the case of a complication) and for society (in the case of development of antibiotic resistance). For all of these reasons, new approaches that reduce the need for topical therapy are beginning to emerge, including intracameral injection, sustained or slow-release drug delivery mechanisms, and the recently introduced "Dropless cataract surgery," which involves intravitreal injection of single-use, compounded combination of antibiotics and corticosteroids...
November 29, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27895936/neovascular-glaucoma-a-review
#18
REVIEW
Gustavo B Rodrigues, Ricardo Y Abe, Camila Zangalli, Savio L Sodre, Flavia A Donini, Danilo C Costa, Andre Leite, Joao P Felix, Marcelo Torigoe, Alberto Diniz-Filho, Homero Gusmão de Almeida
Neovascular glaucoma (NVG) is a secondary glaucoma generally associated with poor visual prognosis. The development of new vessels over the iris and the iridocorneal angle can obstruct aqueous humor outflow and lead to increased intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia, which is most commonly secondary to proliferative diabetic retinopathy or central vein retinal occlusion. The neovascularization process in the eye is driven by the events that alter the homeostatic balance between pro-angiogenic factors, such as the vascular endothelial growth factor and anti-angiogenic factors, such as the pigment-epithelium-derived factor...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27895551/oct4-methylation-mediated-silencing-as-an-epigenetic-barrier-preventing-m%C3%A3-ller-glia-dedifferentiation-in-a-murine-model-of-retinal-injury
#19
Luis I Reyes-Aguirre, Monica Lamas
Müller glia (MG) is the most abundant glial type in the vertebrate retina. Among its many functions, it is capable of responding to injury by dedifferentiating, proliferating, and differentiating into every cell types lost to damage. This regenerative ability is notoriously absent in mammals. We have previously reported that cultured mammalian MG undergoes a partial dedifferentiation, but fails to fully acquire a progenitor phenotype and differentiate into neurons. This might be explained by a mnemonic mechanism comprised by epigenetic traits, such as DNA methylation...
2016: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/27894518/radiation-maculopathy-treated-with-intravitreal-bevacizumab
#20
J L Sánchez-Vicente, A Muñoz-Morales, M P Galván-Carrasco, A Castilla-Lázpita, C Vital-Berral, A Alfaro-Juárez, T Rueda-Rueda
CASE REPORT: A 47 year-old woman with a choroidal melanoma developed a macular oedema secondary to radiation therapy 75 months after brachytherapy plaque. The patient received 3 intravitreal Bevacizumab injections. DISCUSSION: The patient had a good response to bevacizumab treatment. In fact, there was a reduction in the macular oedema measured by optical coherence tomography (OCT) scan, as well as an improvement in best corrected visual acuity. There was no recurrence of macular oedema, and visual acuity remained stable after 3-years follow-up...
November 25, 2016: Archivos de la Sociedad Española de Oftalmología
keyword
keyword
38574
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"